Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study

被引:86
作者
Diener, HC [1 ]
机构
[1] Univ Essen Gesamthsch, Dept Neurol, D-45122 Essen, Germany
关键词
D O I
10.1046/j.1468-2982.1999.019006581.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Two-hundred-and-seventy-eight patients with acute migraine attacks with or without aura were treated in 17 centers with 1.8 g lysine acetylsalicylate i.v. (Aspisol(R);=1 g acetylsalicylic acid), 6 mg sumatriptan s.c. or placebo using a double-blind, double-dummy, randomized, multicenter parallel group study design. Two-hundred-and-seventy-five of them fulfilled the criteria for efficacy analysis, corresponding to 119 patients treated with lysine acetylsalicylate (L-ASA), 114 with sumatriptan and 42 with placebo injections. Both treatments were highly effective compared to placebo (p<0.0001) in decreasing headache from severe or moderate to mild or none (verbal rating scale, VRS, placebo=23.8%). Sumatriptan showed a significantly (p=0.001) better response (91.2%) compared to L-ASA (response 73.9%). Of the patients in the L-ASA-group, 43.7% were pain-free after 2 h; 76.3% after sumatriptan and 14.3% after placebo. It took patients on average 12.6 (L-ASA), 8.2 (sumatriptan), and 19.4 h (placebo) to be able to work again. There was no significant difference between treatment groups in recurrence of headache in responders within 24 h (18.2% L-ASA, 23.1% sumatriptan, 20% placebo). Accompanying symptoms (nausea, vomiting, photophobia, phonophobia, and visual disturbances) improved with both verum treatments to a similar extent. L-ASA was significantly better tolerated than sumatriptan (adverse events L-ASA 7.6%, sumatriptan 37.8%). In conclusion, subcutaneous sumatriptan and lysine acetylsalicylate i.v, are effective treatments for patients suffering from migraine attacks. Sumatriptan is more effective, but resulted in more adverse events.
引用
收藏
页码:581 / 588
页数:8
相关论文
共 8 条
[1]  
FERRARI MD, 1991, NEW ENGL J MED, V325, P316
[2]   SUCCESSFUL TREATMENT OF MIGRAINE ATTACKS WITH INTRAVENOUS-INJECTION OF ASPIRIN [J].
NODA, S ;
ITOH, H ;
UMEZAKI, H ;
FUKUDA, Y .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1985, 48 (11) :1187-1187
[3]   FLUNARIZINE IN PROPHYLAXIS OF CHILDHOOD MIGRAINE - A DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY [J].
SORGE, F ;
DESIMONE, R ;
MARANO, E ;
NOLANO, M ;
OREFICE, G ;
CARRIERI, P .
CEPHALALGIA, 1988, 8 (01) :1-6
[4]   DOUBLE-BLIND-STUDY OF INTRAVENOUS ASPIRIN VS PLACEBO IN THE TREATMENT ACUTE MIGRAINE ATTACKS [J].
TANERI, Z ;
PETERSENBRAUN, M .
SCHMERZ, 1995, 9 (03) :124-129
[5]   Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat [J].
Tfelt-Hansen, P .
CEPHALALGIA, 1998, 18 (08) :532-538
[6]   THE EFFECTIVENESS OF COMBINED ORAL LYSINE ACETYLSALICYLATE AND METOCLOPRAMIDE COMPARED WITH ORAL SUMATRIPTAN FOR MIGRAINE [J].
TFELTHANSEN, P ;
HENRY, P ;
MULDER, LJ ;
SCHELDEWAERT, RG ;
SCHOENEN, E ;
CHAZOT, G .
LANCET, 1995, 346 (8980) :923-926
[7]  
THOMPSON CJ, 1992, EUR NEUROL, V32, P177
[8]   MIGRAINE AND CLUSTER HEADACHE - THEIR MANAGEMENT WITH SUMATRIPTAN - A CRITICAL-REVIEW OF THE CURRENT CLINICAL-EXPERIENCE [J].
WILKINSON, M ;
PFAFFENRATH, V ;
SCHOENEN, J ;
DIENER, HC ;
STEINER, TJ .
CEPHALALGIA, 1995, 15 (05) :337-357